Dutfield .G; Suthersanen .U. “Global Intellectual Property Law”. Edward Elgar Publishing, 2008.
15. Halabi, Sam Foster. “International Trademark Protection and Global Public Health: A Just-Compensation Regime for Expropriations and Regulatory Takings”. Catholic University Law Review, Vol. 61:325, 2012.
http://digitalcommons.law.utulsa.edu/cgi/viewcontent.cgi?article=1257&context=fac_pub, last visited: 12/05/2014.
16. Fink.C. “Intellectual Property and Public Health: An Overview of the Debate with a Focus on U.S. Policy”. Center for Global Development, Working Paper Number 146, 2008.
17. Flynn, Sean; Madhani, Bijan. “ACTA and Access to Medicines”. American University Washington College of Law, PIJIP Research Paper Series, Paper 22. Program on Information Justice and Intellectual Property, 10-6- 2011.
18. Hammond, David. “‘Plain packaging’ regulations for tobacco products: the impact of standardizing the color and design of cigarette packs”. Salud Pública Méx, vol. 52, suppl 2, 2010.
http://www.scielo.org.mx/pdf/spm/v52s2/a18v52s2.pdf. , last visited: 11/30/2014.
19. Germán, Velásquez. “Access to Medicines and Intellectual Property: The Contribution of the World Health Organization”. South Centre, Research Papers 47, 2013. http://apps.who.int/medicinedocs/documents/s20168en/s20168en.pdf, last visited: 09/27/2014.
20. Germán, Velásquez; Pascale, Boulet. “Globalization and Access to Drugs: Implications of the WTO/TRIPS Agreement”. WHO, Geneva, November, 1997.
21. Ghanotakis, Elena. “Access to Medicines for Developing Countries”. Journal of Word IP, vol 7, issue 14, 2004.
22. Hawkins, Loraine. “WHO/HAI Project on Medicine Prices and Availability”. Review Series on Pharmaceutical Pricing Policies and Interventions, Working Paper 4: Competition Policy, WHO/HAI, 2011.
www.haiweb.org/medicineprices/05062011/Competition percent20final percent20May percent202011.pdf. , last visited: 11/03/2014.
23. Henning Grosse Ruse – Khan. “Protecting Intellectual Property under Bits, FTAs, and Trips: Conflicting Regimes or Mutual Coherence?” Cambridge University Press, Max Planck Institute for Intellectual Property and Competition Law Research Paper, No. 11-02, February 7, 2011.
24. Hogerzeil, H.V.; Mirza, Z. “The World Medicines Situation: Access to Essential Medicines as Part of the Right to Health”. WHO, Geneva, 2011.
25. Idris, Kamil. “Intellectual Property A Power Tool For Economic Growth”. World Intellectual Property Organization (WIPO), 2003.
26. Jai Krishna. R; Whalen, Jeanne. “Novartis Loses Glivec Patent Battle in India”. The Wall Street journal, April 1, 2013.
http://www.wsj.com/articles/SB10001424127887323296504578395672582230106. Last visited: 2015/12/01.
27. Kraβer, Rudolf. “Purpose and Limits of the Exclusion from Patentability of Medical Methods, Especially Diagnostic Methods”. In Patents and Technological Progress in a Globalized World. Springer Berlin Heidelberg, MPI Studies on Intellectual Property, Competition and Tax Law Volume 6, 2009.
28. Kulkarni, Kaustubh; Mohanty, Suchitra. “Novarits loses landmark india cancer drug patent case”. REUTERS, Apr 1, 2013.
http://www.reuters.com/article/2013/04/01/us-india-novartis-patent-idUSBRE93002I20130401. Last visited: 2015/12/01.
29. Lazzarini. Z. “Making Access to Pharmaceuticals a Reality: Legal Options under TRIPS and the Case of Brazil”. Yale Human Rights and Development Journal, Vol. 6, Iss. 1, Art. 4, 2003.
http://digitalcommons.law.yale.edu/yhrdlj/vol6/iss1/4/, last visited: 03/22/2015.
30. Locke, John. “Second Treatise of Government”. 1689, last amended: 2008. http://www.earlymoderntexts.com/pdfs/locke1689a.pdf, last visited: 10/09/2014.
31. Maybarduk, Peter. “ACTA and Public Health”. American University Washington College of Law, Pijip Research Paper No. 9, Washington, DC, 9-1-2010.
http://digitalcommons.wcl.american.edu/cgi/viewcontent.cgi?article=1011&context=research, last visited: 11/20/2014.
32. MDG Gap Task Force. “The Global Partnership for Development: Making Rhetoric a Reality”. MDG Gap Task Force Report, United Nations, New York, 2012.
http://www.un.org/millenniumgoals/2012_Gap_Report/MDG_2012Gap_Task_Force_report.pdf, last visited: 09/25/2014.
33. Moodie .C; Bauld .L. “Evidence supports plain tobacco packaging to improve public health”. The pharmaceutical journal, vol 294, no 7843/4, 8 Jan 2015.
http://www.pharmaceutical journal.com/opinion/comment/evidence-supports-plain-tobacco-packaging-to-improve-public health/20067505.article, last visited: 11/28/2014.
34. Moodie .C; Stead .M; Bauld .L et al. “Plain tobacco packaging: A systematic review”. University of Stirling, 2012.
35. Olasupo Ayodeji Owoeye. “Compulsory patent licensing and local drug manufacturing capacity in Africa”. Bull World Health Organ, 2014.
36. Packard Love, James. “Recent examples of the use of compulsory licenses on patents”. Knowledge Ecology International, KEI Research Note 2, 2007.
http://www.keionline.org/misc-docs/recent_cls_8mar07.pdf., last visited: 10/11/2014.
37. Rae, Fiona. “Intellectual Property Rights versus the Right to Access Essential Medicines”. HAI Essay Competition, 2010.
38. Reichman, Jerome; Hasenzahl, Catherine. “Non-Voluntary Licensing Of Patented Inventions, The Canadian Experience”, UNCTUD/ICTSD, October 2002.
39. Reid Smith, Sanya. “Intellectual Property in Free Trade Agreements”. Third World Network (TWN), Malaysia, 2008.
40. Rimmer, Matthew. “Cigarattes will kill you: the high court of astralia & plain packaging of tobacco products”. wipo magazine, February 2013.
http://www.wipo.int/wipo_magazine/en/2013/01/article_0005.html, last visited: 12/03/2014.
41. Roffe .P; Spennemann .Ch. “The impact of FTAs on public health policies and TRIPS flexebilities”. Int.J. Intellectual Property Management, Vol. 1, Nos. 1/2, 2006.
42. Said, Mohammed. “Public health related TRIPS-plus provisions in bilateral trade agreements”. World Health Organization and International Centre for Trade and Sustainable Development, 2010.
43. Shashikant, Sangeeta. “The IMPACT Counterfeit Taskforce, Intellectual Property Rights Enforcement and Seizure of Medicines”. Intellectual Property Rights Series 13, Third World Network (TWN), Malayzia, 2010.
44. Sir Cyril Chantler. “Standardised packaging of tobacco”. Kings College London, April 2014.
http://www.kcl.ac.uk/health/10035-tso-2901853-chantler-review-accessible.pdf, last visited: 12/05/2014.
45. Sisule F. Musungu; Cecilia Oh. “The use of flexibilities in TRIPS by developing countries: can they promote access to medicines?”. Commission on intellectual property rights, innovation and public health (CIPIH), 2005.
http://www.who.int/intellectualproperty/studies/TRIPSFLEXI.pdf. , last visited: 10/17/2014.
46. Stiglitz, Joseph. “Shift from patents regime to prize-based system will revolutionise research and healthcare”. Economic Times, May 21, 2012.
47. Stiglitz, Joseph; Cimoli, Mario et al. “The Role of Intellectual Property Rights in Developing Countries: Some Conclusions”. Intellectual Property Rights: Legal and Economic Challenges for Development, Oxford, UK and New York: Oxford University Press, 2014.
48. Sylvia, Fodor. “Compulsory licensing under the TRIPS-Agreement: a tool for developing countries’ access to technology transfers”. Lund University, 2011.
49. UNDP, HIV/AIDS Group. “HIV and the Law: Risks, Rights and Health”. Global Commission on HIV and the Law, 2012.
http://www.hivlawcommission.org/resources/report/FinalReport-Risks,Rights&Health-EN.pdf, last visited: 10/14/2014.
50. Vadi, Valentina. “Trade Mark Protection, Public Health and International Investment Law: Strains and Paradoxes”. The European Journal of International Law, Vol. 20 no. 3 © EJIL 2009.
51. Visser, Coenraad. “Patent Exceptions and Limitations in the Health Context”. WIPO, SCP/15/3, ANNEX V, 2010.
http://www.wipo.int/edocs/mdocs/scp/en/scp_15/scp_15_3-annex1.pdf, last visited: 10/08/2014.
52. Waning .B; Dietrichsen .E; Moon S. “A Lifetime to Treatment: The Role of Indian Generic Manufacturers in Supplying Antiretroviral Medicines to Developing Countries”. Journal of the International AIDS Society, v.13, 2010.
53. Watal, Jayashree. ““Bolar” exception to patent rights: Some economic implications”. SCP Seminar on Exceptions and Limitations to Patent Rights, WTO, 03.11.2014.
54. WHO; UNITAID. “The Trans-Pacific Partnership Agreement: Implications for Access to Medicines and Public Health”. March 2014.
http://www.unitaid.eu/images/marketdynamics/publications/TPPA-Report_Final.pdf, last visited: 11/10/2014.
55. Wipo. “The Enforcement of Intellectual Property Rights: A Case Book”. 3rd Edition, 2012.
http://www.wipo.int/edocs/pubdocs/en/intproperty/791/wipo_pub_791.pdf, last visited: 11/21/2014.
56. World Health Organization. “Global strategy and plan of action on public health, innovation and intellectual property”. Geneva, 2011.
http://www.who.int/phi/publications/Global_Strategy_Plan_Action.pdf, last visited: 12/03/2014.
57. World Health Organization. “Public Health, Innovation and Intellectual Property Rights”. Commission on Intellectual Property Rights, Innovation and Public Health, (CIPIH), Geneva, 2006.
http://www.who.int/entity/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf, last visited: 09/25/2014.
58. WTO; WHO; WIPO. “Promoting access to medical technologies and innovation: intersections between public health, intellectual property and trade”. Geneva, 2013.
59. Xavier, Seuba; Rovira, Joan; Bloeman, Sophie. “Welfare Implications of Intellectual Property Enforcement Measures”. American University Washington College of Law, PIJIP Research Paper No. 5, Washington, DC, 2010.
60. Yi-Jen Chu. “The Evolution of US and EU Approaches to Intellectual Property Provisions Related to Public Health in Free Trade Agreements: Are They Responding to Public Health Concerns?” Munich
Dutfield .G; Suthersanen .U. “Global Intellectual Property Law”. Edward Elgar Publishing, 2008.